|
Exosomal Drug Delivery
|
1R44CA221487-01
|
$719,680
|
$719,680
|
GUPTA, RAMESH
|
3P BIOTECHNOLOGIES, INC.
|
|
Targeted Therapy for Non Small Cell Lung Carcinoma: Human Phase 1 safety and dose escalation studies
|
2R44CA162629-02A1
|
$1,154,726
|
$288,682
|
SERRERO, GINETTE
|
A AND G PHARMACEUTICAL, INC.
|
|
Core Support for Cancer Center
|
5P30CA013330-45
|
$3,646,138
|
$36,461
|
GOLDMAN, ISRAEL
|
ALBERT EINSTEIN COLLEGE OF MEDICINE, INC
|
|
Inhibition of Senescence to Increase Cancer Cell Death: A New Paradigm
|
5R01CA077263-18
|
$417,500
|
$137,775
|
MCDAID, HAYLEY
|
ALBERT EINSTEIN COLLEGE OF MEDICINE, INC
|
|
Identification of susceptibility to chemotherapy induced peripheral neuropathy using patient stem cell derived sensory neurons
|
1R03CA220219-01
|
$88,500
|
$88,500
|
WOOLF, CLIFFORD
|
BOSTON CHILDREN'S HOSPITAL
|
|
Epigenetically Reversing Paclitaxel Resistance in Triple Negative Breast Cancers
|
1F32CA210426-01A1
|
$61,866
|
$61,866
|
GAYLE, SYLVIA
|
CASE WESTERN RESERVE UNIVERSITY
|
|
Case Comprehensive Cancer Center Support Grant
|
3P30CA043703-27S1
|
$118,875
|
$2,378
|
GERSON, STANTON
|
CASE WESTERN RESERVE UNIVERSITY
|
|
Case Comprehensive Cancer Center Support Grant
|
3P30CA043703-27S2
|
$60,000
|
$1,200
|
GERSON, STANTON
|
CASE WESTERN RESERVE UNIVERSITY
|
|
Case Comprehensive Cancer Center Support Grant
|
3P30CA043703-27S3
|
$200,000
|
$4,000
|
GERSON, STANTON
|
CASE WESTERN RESERVE UNIVERSITY
|
|
Case Comprehensive Cancer Center Support Grant
|
3P30CA043703-27S4
|
$145,821
|
$2,916
|
GERSON, STANTON
|
CASE WESTERN RESERVE UNIVERSITY
|
|
Case Comprehensive Cancer Center Support Grant
|
5P30CA043703-27
|
$4,895,515
|
$97,910
|
GERSON, STANTON
|
CASE WESTERN RESERVE UNIVERSITY
|
|
Targeting BET proteins in Triple Negative Breast Cancer
|
5R01CA206505-02
|
$366,913
|
$183,457
|
KERI, RUTH
|
CASE WESTERN RESERVE UNIVERSITY
|
|
c-Abl-mediated Suppression of Breast Cancer Development and Metastasis
|
5R01CA177069-05
|
$328,265
|
$82,066
|
SCHIEMANN, WILLIAM
|
CASE WESTERN RESERVE UNIVERSITY
|
|
Nanoparticle-mediated treatment for bone metastasis
|
5R01CA206189-02
|
$312,562
|
$312,562
|
LABHASETWAR, VINOD
|
CLEVELAND CLINIC LERNER COM-CWRU
|
|
Total Synthesis and Biosynthesis of Bioactive Substances
|
5R01CA070375-21
|
$256,101
|
$128,051
|
WILLIAMS, ROBERT
|
COLORADO STATE UNIVERSITY
|
|
Dana-Farber/Harvard Cancer Center
|
3P30CA006516-52S2
|
$60,000
|
$600
|
BENZ, EDWARD
|
DANA-FARBER CANCER INST
|
|
Dana-Farber/Harvard Cancer Center
|
3P30CA006516-52S3
|
$100,000
|
$1,000
|
BENZ, EDWARD
|
DANA-FARBER CANCER INST
|
|
Dana-Farber/Harvard Cancer Center
|
2P30CA006516-52
|
$11,592,798
|
$115,928
|
GLIMCHER, LAURIE
|
DANA-FARBER CANCER INST
|
|
Dana-Farber/Harvard Cancer Center
|
3P30CA006516-52S1
|
$112,500
|
$1,125
|
GLIMCHER, LAURIE
|
DANA-FARBER CANCER INST
|
|
(PQ9) The role of Bclw (bcl2l2) in preventing chemotherapy induced neuropathy
|
5R01CA205255-02
|
$577,463
|
$577,463
|
SEGAL, ROSALIND
|
DANA-FARBER CANCER INST
|
|
The mechanism of DNA damage and chromothripsis from chromosome segregation errors
|
5K08CA208008-02
|
$177,120
|
$177,120
|
SPEKTOR, ALEXANDER
|
DANA-FARBER CANCER INST
|
|
Analysis of Blood Borne Markers in Hormone Sensitive Metastatic Prostate Cancer
|
5R01CA208254-02
|
$481,793
|
$144,538
|
SWEENEY, CHRISTOPHER
|
DANA-FARBER CANCER INST
|
|
SPORE: Dana-Farber/Harvard Cancer Center SPORE in Breast Cancer
|
5P50CA168504-05
|
$2,051,965
|
$61,559
|
WINER, ERIC
|
DANA-FARBER CANCER INST
|
|
Perfluorocarbon Nanodroplets for the Detection and Treatment of Nodal Metastases
|
1F30CA216939-01A1
|
$49,044
|
$14,713
|
YARMOSKA, STEVEN
|
EMORY UNIVERSITY
|
|
Chlorotoxin as a Targeting Agent for Cancer Therapies
|
5R01CA135491-09
|
$396,000
|
$198,000
|
OLSON, JAMES
|
FRED HUTCHINSON CANCER RESEARCH CENTER
|
|
Moffitt Cancer Center Support Grant
|
2P30CA076292-19
|
$2,990,966
|
$29,910
|
SELLERS, THOMAS
|
H. LEE MOFFITT CANCER CTR & RES INST
|
|
Moffitt Cancer Center Support Grant
|
3P30CA076292-19S1
|
$125,000
|
$1,250
|
SELLERS, THOMAS
|
H. LEE MOFFITT CANCER CTR & RES INST
|
|
Moffitt Cancer Center Support Grant
|
3P30CA076292-19S2
|
$250,000
|
$2,500
|
SELLERS, THOMAS
|
H. LEE MOFFITT CANCER CTR & RES INST
|
|
A Novel Oncogenic Role for Cdc20 Implications in Adult T Cell Leukemia Treatment
|
5R00CA183914-04
|
$254,171
|
$254,171
|
WAN, LIXIN
|
H. LEE MOFFITT CANCER CTR & RES INST
|
|
Indiana University Melvin and Bren Simon Cancer Center Support Grant
|
3P30CA082709-18S1
|
$106,993
|
$1,070
|
LOEHRER, PATRICK
|
INDIANA UNIV-PURDUE UNIV AT INDIANAPOLIS
|
|
Indiana University Melvin and Bren Simon Cancer Center Support Grant
|
3P30CA082709-18S2
|
$129,129
|
$1,291
|
LOEHRER, PATRICK
|
INDIANA UNIV-PURDUE UNIV AT INDIANAPOLIS
|
|
Indiana University Melvin and Bren Simon Cancer Center Support Grant
|
3P30CA082709-18S3
|
$111,340
|
$1,113
|
LOEHRER, PATRICK
|
INDIANA UNIV-PURDUE UNIV AT INDIANAPOLIS
|
|
Indiana University Melvin and Bren Simon Cancer Center Support Grant
|
3P30CA082709-18S4
|
$174,294
|
$1,743
|
LOEHRER, PATRICK
|
INDIANA UNIV-PURDUE UNIV AT INDIANAPOLIS
|
|
Indiana University Melvin and Bren Simon Cancer Center Support Grant
|
3P30CA082709-18S5
|
$250,000
|
$2,500
|
LOEHRER, PATRICK
|
INDIANA UNIV-PURDUE UNIV AT INDIANAPOLIS
|
|
Indiana University Melvin and Bren Simon Cancer Center Support Grant
|
5P30CA082709-18
|
$2,184,000
|
$21,840
|
LOEHRER, PATRICK
|
INDIANA UNIV-PURDUE UNIV AT INDIANAPOLIS
|
|
NOS1AP as a novel target for treating pathological pain
|
5R01CA200417-02
|
$281,910
|
$93,030
|
HOHMANN, ANDREA
|
INDIANA UNIVERSITY BLOOMINGTON
|
|
Improving delivery of paclitaxel to ovarian cancer via expansile nanoparticles
|
1R43CA213538-01A1
|
$283,122
|
$283,122
|
COLBY, AARON
|
IONIC PHARMACEUTICALS
|
|
Regional Oncology Research Center
|
2P30CA006973-54
|
$7,060,038
|
$70,600
|
NELSON, WILLIAM
|
JOHNS HOPKINS UNIVERSITY
|
|
Regional Oncology Research Center
|
3P30CA006973-54S1
|
$125,000
|
$1,250
|
NELSON, WILLIAM
|
JOHNS HOPKINS UNIVERSITY
|
|
Regional Oncology Research Center
|
3P30CA006973-54S2
|
$60,000
|
$600
|
NELSON, WILLIAM
|
JOHNS HOPKINS UNIVERSITY
|
|
Regional Oncology Research Center
|
3P30CA006973-54S3
|
$25,000
|
$250
|
NELSON, WILLIAM
|
JOHNS HOPKINS UNIVERSITY
|
|
Experimental Therapeutics by targeting Spleen Tyrosine Kinase
|
1R01CA215483-01
|
$374,208
|
$374,208
|
SHIH, IE-MING
|
JOHNS HOPKINS UNIVERSITY
|
|
Anti-CCL25 mAb to treat castration resistant prostate cancer
|
1R41CA214080-01
|
$350,000
|
$175,000
|
SINGH, SHAILESH
|
JYANT, INC.
|
|
Single Cell In Vivo Imaging Technology to Analyze Taxane Nano Formulations in Breast Cancer
|
5K99CA207744-02
|
$179,280
|
$179,280
|
MILLER, MILES
|
MASSACHUSETTS GENERAL HOSPITAL
|
|
Mayo Comprehensive Cancer Center Grant
|
3P30CA015083-43S1
|
$60,000
|
$600
|
DIASIO, ROBERT
|
MAYO CLINIC ROCHESTER
|
|
Mayo Comprehensive Cancer Center Grant
|
3P30CA015083-43S2
|
$75,000
|
$750
|
DIASIO, ROBERT
|
MAYO CLINIC ROCHESTER
|
|
Mayo Comprehensive Cancer Center Grant
|
3P30CA015083-43S3
|
$749,911
|
$7,499
|
DIASIO, ROBERT
|
MAYO CLINIC ROCHESTER
|
|
Mayo Comprehensive Cancer Center Grant
|
5P30CA015083-43
|
$5,815,389
|
$58,154
|
DIASIO, ROBERT
|
MAYO CLINIC ROCHESTER
|
|
Mayo Clinic Ovarian Cancer SPORE
|
5P50CA136393-08
|
$2,300,000
|
$115,000
|
KAUFMANN, SCOTT
|
MAYO CLINIC ROCHESTER
|
|
Assessment of Chemotherapy-Induced Peripheral Neuropathy Susceptibility Using Patient-derived iPSC Technology
|
1R01CA211887-01A1
|
$363,713
|
$363,713
|
STAFF, NATHAN
|
MAYO CLINIC ROCHESTER
|
Total relevant funding to Taxol for this search: $21,807,981
|